Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20244957 | 0.85 | CYP1A2 (0.45) | EPHX2ALDH1A1 | |
| SCHEMBL2417746 | 0.84 | EPHX2 (0.55) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL325039 | 0.84 | EPHX2 (0.55) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL8660094 | 0.84 | EPHX2 (0.55) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL28071070 | 0.83 | EPHX2 (0.62) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL29432739 | 0.82 | EPHX2 (0.50) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL30886997 | 0.80 | EPHX2 (0.51) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL9807140 | 0.80 | EPHX2 (0.51) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL29432654 | 0.80 | EPHX2 (0.51) | EPHX2HTR2CPLD1KDM4EALDH1A1 | |
| SCHEMBL2458557 | 0.80 | EPHX2 (0.51) | EPHX2HTR2CPLD1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2140864-A2 | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | H.Lundbeck A/S (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | BAKTHAVATCHALAM RAJAGOPAL | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082362-A1 | Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure | TRPV1, TRPA1, TRPV5 | EPHX2 1378/4885HTR2C 260/4885PLD1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.